clinical trial · NCT04865237
SARS-CoV-2 Human Challenge Characterisation Study
Imperial College London·N/A·completed·n = 36
Covid19SARS-CoV InfectionCorona Virus InfectionCoronavirusCOVID-19SARS-CoV-2 Virus 1x10^1 TCID50RemdesivirSARS-CoV-2 Virus 1x10^2 TCID50SARS-CoV-2 Virus 1x10^3 TCID50
brief summary
This is a dose optimisation study in healthy adults aged 18-30 who will be experimentally inoculated with SARS-CoV-2. The aim is to cause PCR-confirmed upper respiratory infection in the majority of challenged individuals with minimal or no illness, providing data on the course of COVID-19 and the immune response to SARS-CoV-2 infection. This will establish an optimised dose and study design that will then be used to evaluate the efficacy of treatment and vaccine candidates plus level and duration of immune protection in follow-on trials.
started
Mar 6, 2021
primary completion
Jul 11, 2022
completion
Jul 11, 2022
last updated
May 16, 2025
official title
A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol